Savara (NASDAQ:SVRA) Trading Down 2.8%

Savara Inc (NASDAQ:SVRA) dropped 2.8% on Friday . The stock traded as low as $4.91 and last traded at $4.93. Approximately 675,989 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 1,243,419 shares. The stock had previously closed at $5.07.

Analysts Set New Price Targets

SVRA has been the topic of several recent research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of Savara in a research report on Monday, May 6th. Evercore ISI dropped their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, May 16th. Oppenheimer raised their price target on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. HC Wainwright lifted their target price on shares of Savara from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, Guggenheim lifted their target price on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Savara presently has an average rating of “Buy” and a consensus target price of $11.00.

Savara Trading Down 3.6 %

The company’s 50-day simple moving average is $4.30 and its 200 day simple moving average is $4.63. The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.90 and a current ratio of 14.90.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, sell-side analysts expect that Savara Inc will post -0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently modified their holdings of the stock. Opaleye Management Inc. bought a new stake in shares of Savara in the 1st quarter worth approximately $4,258,000. California State Teachers Retirement System grew its stake in Savara by 411.0% in the 1st quarter. California State Teachers Retirement System now owns 75,986 shares of the company’s stock valued at $378,000 after buying an additional 61,117 shares in the last quarter. AWM Investment Company Inc. purchased a new position in Savara in the 1st quarter valued at approximately $498,000. Janus Henderson Group PLC grew its stake in Savara by 41.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after buying an additional 746,407 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC grew its stake in Savara by 2.3% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after buying an additional 332,706 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.